Nanomicellar eye drops: a review of recent advances.

Expert opinion on drug delivery Pub Date : 2024-03-01 Epub Date: 2024-02-27 DOI:10.1080/17425247.2024.2323208
Valentina Paganini, Patrizia Chetoni, Mariacristina Di Gangi, Daniela Monti, Silvia Tampucci, Susi Burgalassi
{"title":"Nanomicellar eye drops: a review of recent advances.","authors":"Valentina Paganini, Patrizia Chetoni, Mariacristina Di Gangi, Daniela Monti, Silvia Tampucci, Susi Burgalassi","doi":"10.1080/17425247.2024.2323208","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Research on nanotechnology in medicine has also involved the ocular field and nanomicelles are among the applications developed. This approach is used to increase both the water solubility of hydrophobic drugs and their penetration/permeation within/through the ocular tissues since nanomicelles are able to encapsulate insoluble drug into their core and their small size allows them to penetrate and/or diffuse through the aqueous pores of ocular tissues.</p><p><strong>Areas covered: </strong>The present review reports the most significant and recent literature on the use of nanomicelles, made up of both surfactants and amphiphilic polymers, to overcome limitations imposed by the physiology of the eye in achieving a high bioavailability of drugs intended for the therapeutic areas of greatest commercial interest: dry eye, inflammation, and glaucoma.</p><p><strong>Expert opinion: </strong>The results of the numerous studies in this field are encouraging and demonstrate that nanomicelles may be the answer to some of the challenges of ocular therapy. In the future, new molecules self-assembling into micelles will be able to meet the regulatory requirements for marketing authorization for their use in ophthalmic formulations.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"381-397"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17425247.2024.2323208","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Research on nanotechnology in medicine has also involved the ocular field and nanomicelles are among the applications developed. This approach is used to increase both the water solubility of hydrophobic drugs and their penetration/permeation within/through the ocular tissues since nanomicelles are able to encapsulate insoluble drug into their core and their small size allows them to penetrate and/or diffuse through the aqueous pores of ocular tissues.

Areas covered: The present review reports the most significant and recent literature on the use of nanomicelles, made up of both surfactants and amphiphilic polymers, to overcome limitations imposed by the physiology of the eye in achieving a high bioavailability of drugs intended for the therapeutic areas of greatest commercial interest: dry eye, inflammation, and glaucoma.

Expert opinion: The results of the numerous studies in this field are encouraging and demonstrate that nanomicelles may be the answer to some of the challenges of ocular therapy. In the future, new molecules self-assembling into micelles will be able to meet the regulatory requirements for marketing authorization for their use in ophthalmic formulations.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
纳米微粒滴眼液:最新进展综述。
导言:纳米医学技术的研究也涉及眼科领域,纳米微孔就是其中的一种应用。这种方法可用于提高疏水性药物的水溶性及其在眼组织内/通过眼组织的渗透/渗透率,因为纳米微孔能够将不溶性药物封装在其核心中,而且其体积小,能够通过眼组织的水孔渗透和/或扩散:本综述报告了有关使用纳米微孔(由表面活性剂和两亲性聚合物组成)的最新重要文献,这些纳米微孔可以克服眼部生理机能的限制,实现药物的高生物利用度,这些药物主要用于商业利益最大的治疗领域:干眼症、炎症和青光眼:该领域的大量研究结果令人鼓舞,表明纳米微孔可能是解决眼部治疗某些难题的答案。未来,自组装成胶束的新分子将能够满足在眼科制剂中使用的上市许可监管要求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
An opinion on advanced cancer immunotherapy through innovations in PD-1 inhibitor delivery systems. Acceptability of Cyltezo pen among biologics autoinjector patients, autoinjector naïve patients, and healthcare professionals. The potential of nanosystems in disrupting adenosine signaling pathways for tumor immunotherapy. How can nanoemulsions be used for photosensitizer drug delivery? Advanced drug delivery strategies for diabetic retinopathy: a comprehensive review on current medications, delivery methods, device innovations, overcoming barriers, and experimental models.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1